Results 31 to 40 of about 13,099 (221)

Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia

Pharmacological Research, 2022
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
openaire   +2 more sources

The Profile of BCR-ABL1 Fusion Gene in Childhood Leukemia at “Dharmais” Cancer Hospital

Indonesian Journal of Cancer, 2020
Background: BCR-ABL1 fusion gene, which originated from t (9;22), is an important biomarker for diagnosis, therapeutic approach, and prognosis in childhood leukemia.
Mururul Aisyi , Puji Lestari, Siti Nadliroh, Anita Meisita, Didin Solachudin, Dewi Kristanti, Adhitya Bayu Perdana, Bambang Karsono   +7 more
doaj   +1 more source

Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1. [PDF]

PLoS ONE, 2015
Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML).
Pamela Y Ting, Robert Damoiseaux, Björn Titz, Kenneth A Bradley, Thomas G Graeber, Virneliz Fernández-Vega, Thomas D Bannister, Peter Chase, Reji Nair, Louis Scampavia, Peter Hodder, Timothy P Spicer, John Colicelli   +12 more
doaj   +1 more source

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia [PDF]

Vojnosanitetski Pregled, 2021
Introduction. Additional karyotype abnormalities in the Philadelphia-positive (Ph+) clone can emerge during the progression of chronic myeloid leukemia (CML) and are of-ten associated with the resistance to treatment with tyrosine kinase inhibitors (TKI).
Denčić-Fekete Marija, Leković Danijela, Đorđević Vesna, Jovanović Jelica, Todorić-Živanović Biljana, Jaković Ljubomir, Bogdanović Andrija   +6 more
doaj   +1 more source

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ ABL Positivity during Chronic Phase [PDF]

Annals of Laboratory Medicine, 2013
Dear Editor CML is characterized by the clonal expansion of bone marrow hematopoietic cells and is associated with the Philadelphia chromosome [1]. The accelerated phase of CML, which is also known as the blast crisis phase, occurs in patients as the disease progresses.
Park, Sang Hyuk, Chi, Hyun-Sook, Cho, Young-Uk, Jang, Seongsoo, Park, Chan-Jeoung, Im, Ho-Joon   +5 more
openaire   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib [PDF]

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
Zhou, A, Knoche, E M, Engle, E K, Fisher, D A C, Oh, S T   +4 more
openaire   +1 more source

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

Molecular Cancer, 2007
Background Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
Groffen John, Pertz Veerle, Müschen Markus, Trageser Daniel, Zhang Bin, Feldhahn Niklas, Kaur Pavinder, Heisterkamp Nora   +7 more
doaj   +1 more source

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety

Molecules, 2017
In an attempt to develop potent antitumor agents, new 1,3,4-thiadiazole derivatives were synthesized and evaluated for their cytotoxic effects on multiple human cancer cell lines, including the K562 chronic myelogenous leukemia cell line that expresses ...
Mehlika Dilek Altıntop, Halil Ibrahim Ciftci, Mohamed O. Radwan, Belgin Sever, Zafer Asım Kaplancıklı, Taha F. S. Ali, Ryoko Koga, Mikako Fujita, Masami Otsuka, Ahmet Özdemir   +9 more
doaj   +1 more source

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio, Beatriz Albella, Agirre, Xabier, Casado, José A., Pujol, MR, Rio, P, Bueren, Juan, Ariana Jacome, Albella Beatriz, Maria Eugenia Alonso-Ferrero, Juan A Bueren, Alonso-Ferrero, Maria Eugenia, Calasanz, M.J, María Roser Pujol, Hanenberg, H. (H.), Jacome Ariana, Alonso-Ferrero, ME, Hanenberg, H, Perez, L, Pérez-Fuentes, L. (Laura), Agirre, X, Jacome, A, Juan A. Bueren, Jacome, Ariana, Río Paula, Pujol María Roser, Surrallés Jordi, Prosper-Cardoso, F. (Felipe), Pérez Laura, Maria José Calasanz, Pujol i Calvet, M. Roser, Surralles, J. (Jordi), Hanenberg, Helmut, Prosper Felipe, Helmut Hanenberg, Pérez, Laura, Casado, J. (J.A.), Jacome, A. (Ariana), Albella, Beatriz, Bueren, JA, Hanenberg Helmut, Agirre Xabier, Bueren, J.A. (Juan A.), Valeri, A. (Antonio), Rio, P. (Paula), Calasanz-Abinzano, M.J. (Maria Jose), Prosper, F, José A Casado, Laura Pérez, Paula Río, Surrallés i Calonge, Jordi, Río, Paula, Antonio Valeri, Casado José A., Valeri Antonio, Jordi Surrallés, Casado, JA, Calasanz Maria José, Felipe Prosper, Surralles, J, José A. Casado, Calasanz, MJ, Albella, B, Albella, B. (B.), Alonso-Ferrero Maria Eugenia, Valeri, A, Alonso-Ferrero, M. (M.E.), Pujol, M.R. (María Roser), Bueren Juan A., Aguirre-Ena, X. (Xabier), Xabier Agirre, Prosper, Felipe   +71 more
core   +1 more source